Hiroshi Soda

Scopus Author ID Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 18

Top Venues

Thoracic cancer

Acute medicine & surgery

This page only lists publications with an associated author ORCID identifier.

Publications

Fumiko Hayashi, Kazumasa Akagi, Hirokazu Taniguchi, Toyoshi Matsutake, Hiromi Kawahara, Ichiro Sekine, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroshi Soda, Kazuto Ashizawa, Hiroshi Mukae
TIM-3 expression induces resistance to PD-1 inhibitor in G-CSF-producing lung spindle cell carcinoma: A case report. Thoracic cancer (2023)
Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Yasushi Hisamatsu, Ryotaro Morinaga, Ryuta Tagawa, Ryosuke Ogata, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Katsumi Nakatomi, Fumiko Hayashi, Nanae Sugasaki, Akitoshi Kinoshita, Hiroshi Mukae
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. Thoracic cancer (2023)
Ryo Ogata, Hiroshi Soda, Yuichi Fukuda, Hiroshi Mukae
Exploring the ethical complexities of do-not-attempt-resuscitation orders using the approach of advance care planning. Acute medicine & surgery 10 (1) (2023)
Ryuta Tagawa, Hiroshi Soda, Yosuke Dotsu, Hiroaki Senju, Satoshi Irifune, Masataka Yoshida, Shota Nakashima, Asuka Umemura, Keisuke Iwasaki, Hirokazu Taniguchi, Shinnosuke Takemoto, Yuichi Fukuda, Hiroshi Mukae
Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia-inducible factor-1α, vascular endothelial growth factor, and hypervascularization. Thoracic cancer (2023)
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study. Thoracic cancer 13 (16) (2022)
Ryosuke Ogata, Hiroshi Soda, Hiroaki Senju, Masaki Fujioka, Midori Shimada, Koki Yamashita, Satoshi Irifune, Ryuta Tagawa, Yosuke Dotsu, Keisuke Iwasaki, Hirokazu Taniguchi, Shinnosuke Takemoto, Yuichi Fukuda, Hiroshi Mukae
Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: A case of pleural metastases. Thoracic cancer 13 (19) (2022)
Ryosuke Ogata, Hiroshi Soda, Yasuhiro Tanaka, Hiroaki Senju, Midori Shimada, Koki Yamashita, Shota Nakashima, Asuka Umemura, Masataka Yoshida, Takuya Hara, Saeko Jinnai, Keisuke Iwasaki, Yuichi Fukuda, Hiroyuki Yamaguchi, Hiroshi Mukae
Onset of pulmonary Epstein-Barr virus-positive diffuse large B-cell lymphoma in a patient with silicosis. Thoracic cancer (2021)
Yasuhiro Tanaka, Hiroshi Soda, Yuichi Fukuda, Kenta Nio, Sawana Ono, Hiromi Tomono, Midori Shimada, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Keisuke Iwasaki, Hiroyuki Yamaguchi, Hiroshi Mukae
Vildagliptin-induced ground-glass nodules mimicking lung metastases in a cancer patient receiving Lactobacillus probiotic supplementation. Thoracic cancer 11 (2) (2020)
Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. Thoracic cancer 11 (7) (2020)
Hirokazu Taniguchi, Hiroyuki Yamaguchi, Yosuke Dotsu, Midori Shimada, Hiroshi Gyotoku, Hiroaki Senju, Shinnosuke Takemoto, Takeshi Kitazaki, Masaaki Fukuda, Daiki Ogawara, Hiroshi Soda, Katsumi Nakatomi, Nanae Sugasaki, Akitoshi Kinoshita, Seiji Nagashima, Takaya Ikeda, Yoichi Nakamura, Noriho Sakamoto, Yasushi Obase, Minoru Fukuda, Hiroshi Mukae
Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. Thoracic cancer 10 (9) (2019)
Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae
Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic cancer 11 (2) (2019)
Hiromi Tomono, Hiroshi Soda, Yuichi Fukuda, Yasuhiro Tanaka, Sawana Ono, Midori Shimada, Keisuke Iwasaki, Masashi Hisanaga, Hiroyuki Yamaguchi, Hiroshi Mukae
Intrathoracic amyloid tumors that presented as yellowish multinodular endobronchial protrusions with irregular vascularity and easy bleeding. Thoracic cancer 10 (10) (2019)
Daiki Ogawara, Hiroshi Soda, Hiromi Tomono, Keisuke Iwasaki, Takuya Hara, Saeko Jinnai, Takatomo Funayama, Daisuke Okuno, Hirokazu Taniguchi, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Yuichi Fukuda, Hiroyuki Yamaguchi, Hiroshi Mukae
Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series. Thoracic cancer 9 (10) (2018)
Hiroshi Soda, Daiki Ogawara, Yuichi Fukuda, Hiromi Tomono, Daisuke Okuno, Seiko Koga, Hirokazu Taniguchi, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Hiroyuki Yamaguchi, Hiroshi Mukae
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study. Thoracic cancer 10 (2) (2018)
Takayuki Suyama, Yuichi Fukuda, Hiroshi Soda, Daiki Ogawara, Keisuke Iwasaki, Takuya Hara, Masataka Yoshida, Tatsuhiko Harada, Asuka Umemura, Hiroyuki Yamaguchi, Hiroshi Mukae
Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G. Thoracic cancer 9 (6) (2018)
Kazuaki Okamura, Yuichi Fukuda, Hiroshi Soda, Daiki Ogawara, Keisuke Iwasaki, Shinichiro Fuchi, Takayuki Suyama, Masataka Yoshida, Tatsuhiko Harada, Minoru Fukuda, Hiroshi Mukae
Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab. Thoracic cancer 9 (1) (2017)
Daiki Ogawara, Hiroshi Soda, Keisuke Iwasaki, Takayuki Suyama, Hirokazu Taniguchi, Yuichi Fukuda, Hiroshi Mukae
Remarkable response of nivolumab-refractory lung cancer to salvage chemotherapy. Thoracic cancer 9 (1) (2017)
Daiki Ogawara, Hiroshi Soda, Takayuki Suyama, Masataka Yoshida, Tatsuhiko Harada, Yuichi Fukuda, Hiroshi Mukae
Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M. Thoracic cancer 9 (1) (2017)

Hiroshi Soda.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiroshi Soda